Characteristics | Total(%) | Univariate analysis | Â | Multivariate regression | ||
---|---|---|---|---|---|---|
COR (95%CI) | P | Â | AOR (95%CI) | P | ||
Gender, male | 510(40.99) | 1.19(0.68–2.14) | 0.54 |  |  |  |
Age group,<65year | 509(40.92) | 0.73(0.40–1.30) | 0.30 |  |  |  |
BMI_level<30 | 751(60.37) | 0.88(0.35–2.97) | 0.81 |  |  |  |
Hypertension | 611(49.12) | 0.92(0.53–1.60) | 0.76 |  |  |  |
Diabetes | 344(27.65) | 4.11(2.36–7.29) | 8.09e-07 |  | 2.78(1.61–4.86) | 0.0002 |
Tumor | 307(24.68) | 1.35(0.73–2.40) | 0.32 |  |  |  |
Kidney disease | 443(35.61) | 1.93(1.11–3.38) | 0.02 |  |  |  |
Neurological disease | 389(31.27) | 2.07(1.19–3.61) | 0.01 |  | 1.93(1.11–3.35) | 0.02 |
Invasive ventilation | 153(12.29) | 3.57(1.91–6.44) | < 0.001 |  |  |  |
Urinary catheter | 393(31.59) | 4.64(2.62–8.47) | < 0.001 |  | 2.28(1.24–4.27) | 0.01 |
Central venous catheter | 290(23.31) | 5.10 (2.91–9.11) | 1.76e-08 |  | 2.53(1.39–4.64) | 0.002 |
Operation | 243(19.53) | 0.92(0.43–1.78) | 0.81 |  |  |  |
ICU admission | 77(6.19) | 2.44(0.98–5.27) | 0.04 |  |  |  |
IL-6_level<10 pg/ml | 388(31.19) | 1.75(1.04–2.94) | 0.03 |  | 1.69(0.97–2.94) | 0.06 |
CRP_level<10 mg/L | 589(47.35) | 0.35(0.18–0.63) | < 0.001 |  |  |  |
PCT_level > 0.5 ng/ml | 163(13.10) | 4.00(2.33–7.14) | < 0.001 |  | 2.03(1.41–3.82) | 0.03 |
Cr_level<44 umol/L | 907(72.91) | 0.29(0.14–0.43) | < 0.001 |  | 0.40(0.22–0.71) | 0.002 |
WBC_level<9.5 × 109/L | 988(79.42) | 0.63 (0.34–1.22) | 0.15 |  |  |  |
Ne_level < 80% | 859(69.05) | 0.40(0.24–0.67) | 0.0005 |  |  |  |
Lym_level<0.2 × 109/L | 6(0.48) | 5.71(0.29–39.42) | 0.12 |  |  |  |
ALB_level<35 g/L | 513(41.24) | 2.85(1.62–5.20) | 0.0004 |  |  |  |
Hb_level<120 g/L | 601(48.31) | 1.15(0.69–1.92) | 0.59 |  |  |  |
Dexamethasone(DXM) | 368(29.58) | 2.59(1.49–4.52) | 0.001 |  |  |  |
Meprednisone (MEP) | 430(34.57) | 1.46(0.83–2.55) | 0.18 |  |  |  |
Tocilizumab(TZ) | 14(1.12) | 1.74(1.00–9.00) | 0.60 |  |  |  |
Length of hospital stay<7days | 263(21.14) | 1.09(0.57–1.96) | 0.78 |  |  |  |